Stroke:心房颤动患者卒中的一级预防与二级预防!

2017-07-06 xing.T MedSci原创

只有约半数符合条件的房颤患者按照指南进行口服抗凝治疗。指南依从的抗栓治疗显著降低了一级预防患者的卒中风险,以及减少了既往卒中患者复发性卒中和死亡的风险。

虽然经历了急性脑卒中房颤(AF)患者具有较高的复发风险,许多患者未经治疗或不是最佳的卒中预防治疗。近日,卒中领域权威杂志Stroke上发表了一篇研究文章,该研究的目的是在当代初级保健人群中比较既往有和无卒中的AF患者与指南依从性抗栓治疗相关的临床结局。

研究人员采用含有105000例患者的社区队列来评估2014国家健康和护理卓越指南的AF卒中预防策略。

该研究共发现了2259例(2.15%)AF患者,其中18.9%例组建了二级预防队列。对于二级预防,抗血栓治疗指南依从率为56.3%、18.9%的患者过度治疗,并且24.8%的患者治疗不足;初级预防相应的比例分别为49.5%、11.7%和38.8%。一级预防和二级预防1年后卒中发生率分别为8.6%和1.6%(P<0.001),相应的全因死亡率分别为9.8%和9.4%(P=0.79)。在多变量分析中,抗血栓治疗指南依从性的缺乏与增加的卒中危险因素一级预防相关(治疗不足比值比为2.95;95%可信区间为1.26-6.90;P=0.013);对于二级预防,指南依从性缺乏与卒中复发(过度治疗的比值比为2.80;95%可信区间为1.25-6.27;P=0.012)和全因死亡率(治疗不足比值比为2.75;95%可信区间为1.33-5.69;P=0.006)风险增加相关。

只有约半数符合条件的房颤患者按照指南进行口服抗凝治疗。指南依从的抗栓治疗显著降低了一级预防患者的卒中风险,以及减少了既往卒中患者复发性卒中和死亡的风险。

原始出处:

Michał Mazurek, et al. Secondary Versus Primary Stroke Prevention in Atrial Fibrillation Insights From the Darlington Atrial Fibrillation Registry.Stroke. 2017. https://doi.org/10.1161/STROKEAHA.116.016146

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1626847, encodeId=2cd8162684e4a, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Jul 08 00:37:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219147, encodeId=40cd21914ea8, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Jul 06 11:37:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219122, encodeId=ae39219122b0, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Jul 06 10:07:06 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-08 sodoo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1626847, encodeId=2cd8162684e4a, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Jul 08 00:37:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219147, encodeId=40cd21914ea8, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Jul 06 11:37:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219122, encodeId=ae39219122b0, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Jul 06 10:07:06 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 明天会更好!

    学习了,谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1626847, encodeId=2cd8162684e4a, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sat Jul 08 00:37:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219147, encodeId=40cd21914ea8, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Jul 06 11:37:19 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219122, encodeId=ae39219122b0, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Thu Jul 06 10:07:06 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 明月清辉

    谢谢分享,学习了

    0